Kan Kikuchi
Internal medicineUrologyEndocrinologyInfection controlIntensive care medicinePropensity score matchingMortality rateCohort studyImmunologyHazard ratioHepatitis C virusHepatitis CHemodialysisKidney diseaseDialysisCoronavirus disease 2019 (COVID-19)Dialysis patientsIncidence (epidemiology)Confidence intervalProportional hazards modelNephrologyDiabetes mellitusMedicinePandemicGastroenterology
31Publications
10H-index
250Citations
Publications 31
Newest
#1Yuka Sugawara (UTokyo: University of Tokyo)H-Index: 1
#2Masao Iwagami (Lond: University of London)H-Index: 9
Last. Masaomi Nangaku (UTokyo: University of Tokyo)H-Index: 80
view all 12 authors...
BACKGROUND: There are no reports of a large-scale survey on the infection prevention measures against coronavirus disease 2019 (COVID-19) in nephrology facilities. This study investigated the facility-level nephrology practices adopted during the COVID-19 pandemic and their associated challenges. Additionally, the treatment patterns and outcomes of chronic kidney disease (CKD) patients with COVID-19 were reviewed. METHODS: We conducted a nationwide questionnaire survey of 704 educational facilit...
Source
#1Hidenori ToyodaH-Index: 63
#2Kan KikuchiH-Index: 10
Last. Junko Tanaka (Hiroshima University)H-Index: 28
view all 6 authors...
Background Patients undergoing dialysis are at risk of hepatocellular carcinoma (HCC) and preferably should undergo HCC surveillance. We investigated the utility of HCC tumor markers for HCC surveillance in patients undergoing dialysis. Methods Three serum markers specific for HCC, namely alpha-fetoprotein (AFP), Lens culinaris agglutinin A-reactive fraction of AFP (AFP-L3) and des-gamma-carboxy prothrombin (DCP), were measured in dialysis patients with and without a diagnosis of HCC (n = 60 and...
Source
#1Yukio Maruyama (Jikei University School of Medicine)H-Index: 18
#2Eiichiro Kanda (Kawasaki Medical School)H-Index: 16
Last. Kosaku NittaH-Index: 61
view all 7 authors...
BACKGROUND The prevalence and severity of anemia differ between diabetic and non-diabetic patients. We investigated whether the effect of hemoglobin (Hb) on patient outcome was affected by the presence or absence of diabetes among Japanese patients receiving chronic hemodialysis (HD). METHODS We enrolled 149,308 patients from a nationwide dialysis registry in Japan at the end of 2012 (mean age, 67.6 ± 12.3 years; male, 61.7%; diabetes, 43.5%; median dialysis duration, 65 months) who underwent th...
1 CitationsSource
Background Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic affecting a variety of medical treatments, including hemodialysis. This study aims to investigate the implementation of infection control measures, to examine the shortage of personal protective equipment (PPE) and disinfectants, and to quantify the number of nosocomial COVID-19 transmissions in hemodialysis facilities in Japan during the pandemic. ...
Source
#1Ko HanaiH-Index: 12
#2Makoto AkamatsuH-Index: 2
Last. Tetsuya BabazonoH-Index: 30
view all 50 authors...
The association of glycated albumin (GA) with mortality is unclear in chronic hemodialysis patients with diabetes. We investigated the usefulness of GA by comparing it with hemoglobin A1c (HbA1c) in this patient population. This was a multi-center, prospective cohort study of 841 Japanese chronic hemodialysis patients with diabetes. There were 235 women and 606 men included, with a mean age of 64 years. The primary and secondary endpoints were the incidence of all-cause and cause-specific mortal...
Source
#1Kan KikuchiH-Index: 10
#2Masaomi Nangaku (UTokyo: University of Tokyo)H-Index: 80
Last. Tadao Akizawa (Memorial Hospital of South Bend)H-Index: 1
view all 11 authors...
In Japan, the first case of COVID-19 in dialysis patients was reported on March 1, 2020. A total of 31 cases were reported by April 10, and it increased to 95 by May 15. Thereafter, with the rapid increase in the number of COVID-19 cases in the general population since late March, there was a not surprising increase in the number of COVID-19 cases in dialysis patients. The mortality rate is 16.2% (16/99 cases) in dialysis patients, which is higher than 5.3% (874/16532 cases) in the general popul...
20 CitationsSource
#1Ryoichi AndoH-Index: 14
#2Yasuhiro AsahinaH-Index: 37
Last. Hiroshi Yotsuyanagi (UTokyo: University of Tokyo)H-Index: 41
view all 17 authors...
The Drafting Committee for Hepatitis Management Guidelines established by the Japan Society of Hepatology published the first version of the Guidelines for the Management of Hepatitis B in 2013 (first English version in 2014), and has since been publishing updates to the Guidelines as new drugs become available, with the latest original Japanese version being Version 3.1. Herein, the Drafting Committee publishes the second English version that contains all the changes made since the first Englis...
11 CitationsSource
#1Eiichiro Kanda (Kawasaki Medical School)H-Index: 16
#2Bogdan I. Epureanu (UM: University of Michigan)H-Index: 25
Last. Kosaku NittaH-Index: 61
view all 9 authors...
BACKGROUND Although dialysis patients are at a high risk of death, it is difficult for medical practitioners to simultaneously evaluate many inter-related risk factors. In this study, we evaluated the characteristics of hemodialysis patients using machine learning model, and its usefulness for screening hemodialysis patients at a high risk of one-year death using the nation-wide database of the Japanese Society for Dialysis Therapy. MATERIALS AND METHODS The patients were separated into two data...
3 CitationsSource
#1Ryoichi AndoH-Index: 14
#2Yasuhiro Asahina (Tokyo Medical and Dental University)H-Index: 37
Last. Hiroshi Yotsuyanagi (UTokyo: University of Tokyo)H-Index: 41
view all 17 authors...
The Drafting Committee for Hepatitis Management Guidelines established by the Japan Society of Hepatology drafted the first version of the clinical practice guidelines for the management of hepatitis C virus (HCV) infection in 2012. Since then, we have been publishing updates as new drugs for hepatitis C become available and new indications for existing drugs are added. The new approval of sofosbuvir/velpatasvir prompted us to publish the seventh version of the guidelines in Japanese in March 20...
5 CitationsSource
#1Hiroki Ikeda (St. Marianna University School of Medicine)H-Index: 12
#2Tsunamasa Watanabe (St. Marianna University School of Medicine)H-Index: 18
Last. Takashi KumadaH-Index: 60
view all 39 authors...
: Based on high efficacy and safety demonstrated in clinical trials, treatment with glecaprevir/pibrentasvir (G/P) for 8 weeks is recommended for hepatitis C virus (HCV)-infected patients who are direct-acting antiviral (DAA) naive, genotype 1 or 2, and noncirrhotic. The aim of this study was to validate real-world experience with 8-week G/P treatment in Japan. We conducted a prospective observational cohort study in 554 patients who underwent 8-week treatment from among 1,022 patients who initi...
9 CitationsSource